Results 11 to 20 of about 1,129 (187)

Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. [PDF]

Transl Res, 2014
We have shown that glycemic control prevents diabetes‐mediated remodeling of the cerebrovasculature. However, whether the remodeling can be reversed is unknown. Given that angiotensin II Type 1 receptor blockers (ARBs) reverse pathological vascular remodeling and function independent of changes in blood ...
Abdelsaid M, Coucha M, Ergul A.
europepmc   +4 more sources

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis. [PDF]

Cureus, 2023
This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesartan-medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with hypertension. Systematic searches were conducted on PubMed, Google Scholar, and ClinicalTrials.gov, starting from their establishment until March 15, 2023.
Kumar L, Khuwaja S, Kumar A, Memon UA, Kumar M, Ashok A, Lohana M, Qudoos A, Kashif M, Khatri M, Kumar S, Sapna F, Dass A, Varrassi G.   +13 more
europepmc   +3 more sources

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension [PDF]

Clinical Hypertension, 2018
Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week ...
Attila Juhasz, Jingtao Wu, Michie Hisada, Tomoka Tsukada, Myung Ho Jeong   +4 more
doaj   +2 more sources

Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction [PDF]

Рациональная фармакотерапия в кардиологии, 2022
Aim. To study the effects of azilsartan medoxomil/chlorthalidone (AZM/CTD) and losartan/hydrochlorothiazide (LOS/HCT) combinations for NTproBNP levels, 6-minute walk test results, hydration status along with their antihypertensive efficacy according to ...
Zh. D. Kobalava, A. F. Safarova, Kh. M. Gudieva, M. A. Markova, A. E. Petrosyan   +4 more
doaj   +3 more sources

Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. [PDF]

J Clin Hypertens (Greenwich), 2017
This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs fixed‐dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160–190 mm Hg).
Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A.   +4 more
europepmc   +4 more sources

Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis [PDF]

Frontiers in Cardiovascular Medicine
BackgroundAngiotensin II receptor blockers (ARBs) are utilized for the management of hypertension and diabetes. Previous meta-analyses suggested that azilsartan medoxomil (AZL-M) improved blood pressure (BP) reduction, but there were no safety findings ...
Ling Zhu, Guo-Cui Wei, Qing Xiao, Qian-Lan Chen, Qian Zhao, Xiu-xia Li, Ling-ai Pan, Xuan Xiong   +7 more
doaj   +2 more sources

Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals. [PDF]

Anal Chem Insights, 2014
The recently approved angiotensin II receptor blocker, azilsartan medoxomil (AZL), was determined spectrophotometrically and spectrofluorimetrically in its combination with chlorthalidone (CLT) in their combined dosage form.
Ebeid WM, Elkady EF, El-Zaher AA, El-Bagary RI, Patonay G.   +4 more
europepmc   +5 more sources

Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. [PDF]

J Clin Hypertens (Greenwich), 2018
An open‐label, long‐term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL‐M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up‐titrated (AZL‐M/CLD to 40/25 
Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S.   +6 more
europepmc   +4 more sources

MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL

Российский кардиологический журнал, 2017
Modern approaches to antihypertension therapy suppose the usage of combination drugs, making significant positive influence on the values of systemic blood pressure (BP) in daily and nocturnal periods, optimization of 24-hour BP profile, achieved target ...
V. V. Skibitsky, A. V. Fendrikova
doaj   +3 more sources

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. [PDF]

Blood Press Monit, 2014
The aim of the study was to measure the effects on blood pressure (BP) of the angiotensin receptor blocker azilsartan medoxomil, in 40 and 80 mg doses, combined with 5 mg of the calcium channel blocker amlodipine and to compare these effects with placebo plus amlodipine 5 mg.This was a randomized, controlled, double-blind study of 6 weeks' duration in ...
Weber MA, White WB, Sica D, Bakris GL, Cao C, Roberts A, Kupfer S.   +6 more
europepmc   +4 more sources